Background: Fibromyalgia is a common condition characterised by chronic widespread musculoskeletal pain and central sensitivity features. Appropriate management requires a multidisciplinary approach prioritising non-pharmacological strategies. Evidence-based fibromyalgia medications are not always easily available, effective or tolerated.
Aim: To characterise actual medication usage in Australian fibromyalgia patients.
Methods: Demographic and clinical data, including medication use information, were gathered by chart review from patients attending the Monash Fibromyalgia Clinic between January 2019 and June 2022. Eligible patients were invited to complete an anonymous questionnaire between June and August 2022 to assess current therapeutic use. The questionnaire assessed fibromyalgia clinical features by using the Revised Fibromyalgia Impact Questionnaire and the 2016 modified American College of Rheumatology Fibromyalgia criteria.
Results: The chart review included 474 patients, and 108 participants completed the questionnaire. Most chart review (78.7%) and questionnaire participants (85.2%) reported using at least one medication for their fibromyalgia. 48.5% of chart review patients and 58.3% of questionnaire participants reported using at least one evidence-based medication, usually amitriptyline, duloxetine or pregabalin. However, the most common individual medications for questionnaire participants were non-steroidal anti-inflammatory drugs (48.2%), paracetamol (59.3%) and opioids (34.3%), with most opioids being typical opioids. Among questionnaire participants, 14.8% reported using cannabinoids, and 70.4% reported using at least one supplement, vitamin or herbal/naturopathic preparation. Not all medication or substance use was recorded during clinic appointments.
Conclusion: Fibromyalgia patients engage in various pharmacotherapeutic strategies that are not always evidence-based or disclosed to their treating clinicians.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/imj.16257 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Non-medicinal oral contrast in upper abdominal MRI for MR-guided radiotherapy: A scoping review.
Radiography (Lond)
January 2025
Radiotherapy, Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, UK; Leeds Institute of Medical Research, University of Leeds, Leeds, UK; NIHR Leeds Biomedical Research Centre, Leeds, UK.
Introduction: Using non-medicinal oral contrast agents may aid safe delivery of magnetic resonance image-guided (MR-guided) radiotherapy by improving the ability to visualise and avoid excessive radiation dose to adjacent bowel/stomach. This scoping review aims to map the literature on non-medicinal oral contrasts used in upper-abdominal diagnostic or therapeutic magnetic resonance imaging (MRI) to find potential candidates for employing in MR-guided radiotherapy and identify gaps in knowledge for further study.
Methods: A scoping review of non-medicinal oral contrast used in upper-abdominal MRI research followed a pre-defined protocol based on Arksey and O'Malley's framework.
Clinical patterns and outcomes of patients affected by primary malignant melanoma of the oral mucosa: A European multicenter retrospective chart review.
J Craniomaxillofac Surg
January 2025
Department of Oral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Introduction: The purpose of this European multicenter study was to describe and assess the characteristics, diagnosis, management, and recurrence of oral malignant melanoma at different European oral and maxillofacial surgery centers.
Materials And Methods: This study was based on a systematic computer-assisted database that allowed the recording of data for all primary oral mucosal melanomas treated in the involved surgical units across Europe between January 1, 2003 and December 31, 2022. The following data were recorded for each patient: gender, age, site, TNM staging, metastases, symptoms, imaging features, histopathological features, treatment, complications, recurrence, follow up, and survival.
Determining the process components of impact assessment in health and social program implementation: A scoping review of theories, models and frameworks.
Public Health
January 2025
Health Research Institute, Faculty of Health, University of Canberra, ACT, Australia.
Objectives: Health and social service research impact analysis play a pivotal role in demonstrating research value. Impact analysis of programs, interventions, or policies in real-world settings is complex. There are many implementation evaluation theories, models, and frameworks (TMF) and researchers find choosing one challenging.
View Article and Find Full Text PDFUse of the Adaptive Behaviour Dementia Questionnaire in a Down Syndrome Specialty Clinic.
J Integr Neurosci
January 2025
Down Syndrome Program, Division of Medical Genetics and Metabolism, Department of Pediatrics, Massachusetts General Hospital, Boston, MA 02114, USA.
Objective: To study the use of a dementia screening tool in our clinic cohort of adults with Down syndrome.
Study Design: A retrospective chart review of patients with Down syndrome was conducted to follow the use of the Adaptive Behaviour Dementia Questionnaire (ABDQ) in a dementia screening protocol. The ABDQ results for patients aged 40 years and older at a Down syndrome specialty clinic program were assessed.
Patterns of Treatment and Real-World Outcomes of Patients With Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations Receiving Mobocertinib: The EXTRACT Study.
Cancer Med
February 2025
Pulmonology and Thoracic Oncology Department, APHP Hôpital Tenon and Sorbonne Université, Paris, France.
Background: Real-world data regarding patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion (ex20ins) mutations receiving mobocertinib are limited. This study describes these patients' characteristics and outcomes.
Methods: A chart review was conducted across three countries (Canada, France, and Hong Kong), abstracting data from eligible patients (NCT05207423).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!